UNSPSC 51281673: Streptomycin b

This classification denotes an aminoglycoside antibiotic with the molecular formula C27H49N7O17, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CJ1467C885, chemically known as d-streptamine, o-.beta.-d-mannopyranosyl-(1->4)-o-2-deoxy-2-(methylamino)-.alpha.-l-glucopyranosyl-(1->2)-o-5-deoxy-3-c-formyl-.alpha.-l-lyxofuranosyl-(1->4)-n1,n3-bis(aminoiminomethyl)-, but more generally known as streptomycin b, which bears US NIH Compound Identifier 121307.

UNSPSC 51281673 Streptomycin B is a Commodity code that in practice covers pharmaceutical products procured through state and local health and safety programs, though recent solicitation activity shows minimal direct alignment with the streptomycin antibiotic product itself. State and local health departments and county public-health bodies use this code tier to tag pharmaceutical warehouse orders, emergency medical supplies, and health-intervention products acquired through cooperative purchasing vehicles and competitive bidding. The actual products being solicited under related pharmaceutical codes in this space include antibiotics, opioid-reversal agents, and drug-deactivation systems supplied through established vendor relationships and multi-year contracts with renewal options.

Recent activity appears sparse under this specific code. The Illinois Department of Public Health awarded a $2,999,999.11 three-year pharmaceutical warehouse piggyback contract through MMCAP Infuse to Chartwell Rx LLC (Invitation for Bid, completed August 28, 2026) for Doxycycline Hyclate and Ciprofloxacin Hydrochloride tablets—neither streptomycin—sourced through consolidated purchasing. Seminole County, Florida issued an IFB (due July 26, 2023) for annual procurement of 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems with quarterly deliveries, also outside the streptomycin scope. Geographic activity concentrates in the Southeast and Midwest where public-health agencies leverage cooperative purchasing and fixed-fee competitive bidding for pharmaceutical and medical-supply acquisition, but the code shows little direct recent solicitation for streptomycin-class products specifically.